Outpace Bio Raises $30M in Series A Funding
Summary
Founded by Lyell co-founders Marc Lajoie and Scott Boyken, along with a scientific team that spun out of Lyell Immunopharma, Outpace Bio is creating smart cell therapies using protein design and synthetic biology. The company collaborates with industry leaders, incorporating their biological insights and clinical expertise to create mechanism-driven solutions to improve the safety and efficacy of cell and gene therapies. Its platform combines the design of improved biological functions with cellular control modalities, harnessing the full complexity of cellular biology to tackle incurable disease. For the past two years the team has worked together to solve long-standing problems facing anticancer T cell therapies. In addition to closing the financing round, Outpace has entered into a collaboration with Lyell Immunopharma for joint research and subsequent development and commercialization by Lyell of a potential immune cell therapy for the treatment of cancer.